PanGen Biotech Inc. (222110.KQ) Stock
PanGen Biotech Inc.

Company profile
PanGen Biotech reported revenue of 13.42 billion KRW for fiscal year 2025, down 8.6% from fiscal year 2024, and net income of 2.05 billion KRW. That is a net profit margin of 15.3% for fiscal year 2025. Our analysis of its filings shows revenue growing from 7.32 billion KRW in fiscal year 2023 to 13.42 billion KRW in fiscal year 2025, 35.4% a year on average.
What stands out
- Net income more than doubled in fiscal year 2025, from 943.69 million KRW in fiscal year 2024.
Figures from company filings; latest fiscal year ended December 31, 2025.
About PanGen Biotech Inc.
PanGen Biotech Inc. operates as a biologics company in South Korea. It develops biosimilar products, such as EPO, recombinant factor VIII, G-CSF, etc. The company also provides CHO cell lines for proteins and monoclonal antibodies; and one-stop services ranging from producer cell line development to GMP production. In addition, it offers reagents, quantitation kits, and cell based assay systems, as well as technology transfer service. PanGen Biotech Inc. was founded in 1999 and is based in Suwon-si, South Korea.
Largest shareholders
- Huons Co., Ltd.36.61%
- Duopharma Biotech5.97%
- Jae-Seung Yoon2.96 %2.96%
- Hee-sang Yoon1.054 %1.05%
- Gyu-Yeon Lee0.0333 %0.03%
Share of the company, as of September 25, 2026
Leadership
- Jaeseung Yoon — President & CEO, 64
How much revenue does PanGen Biotech make?
PanGen Biotech reported 13.42 billion KRW in revenue for fiscal year 2025, down 8.6% from 14.67 billion KRW in fiscal year 2024.
What companies are similar to PanGen Biotech?
Listed companies of a similar size in the same industry (various healthcare equipment manufacturing) include Humedix Co., Ltd. (200670.KQ), Synergy Innovation Co., Ltd. (048870.KQ), Selvas Healthcare, Inc. (208370.KQ).
Has PanGen Biotech made a profit in recent years?
Net income by fiscal year: FY2021, a loss of 3.31 billion KRW; FY2022, a loss of 4.49 billion KRW; FY2023, a loss of 4.49 billion KRW; FY2024, 943.69 million KRW; FY2025, 2.05 billion KRW. It reported a net loss in 3 of these 5 years.
Company Information
Contact & Links
Data as of .
How to cite: DataPorium, “PanGen Biotech Inc. (222110.KQ)”, data as of Sep 25, 2026, https://dataporium.tech/stocks/222110.KQ